Английская Википедия:ADB-CHMINACA

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Drugbox

ADB-CHMINACA (also known as MAB-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.289 nM and was originally developed by Pfizer in 2009 as an analgesic medication.[1][2] It was identified in cannabinoid blends in Japan in early 2015.[3]

Side effects

There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid.[4][5][6][7][8][9][10][11]

Legal status

In the United States, ADB-CHMINACA is a Schedule I controlled substance.[12] Prior to its listing at the federal level in 2018, Louisiana placed ADB-CHMINACA on its Schedule I list by emergency scheduling in 2014.[13]

Sweden's public health agency suggested to classify ADB-CHMINACA as hazardous substance on November 10, 2014.[14]

ADB-CHMINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.[15]

ADB-CHMINACA is illegal in Switzerland as of December 2015.[16]

Metabolism

Ten ADB-CHMINACA major metabolites were identified in several incubations with cryopreserved human hepatocytes. Most transformations occurred at the cyclohexylmethyl tail of the compound.[17]

See also

Шаблон:Div col

Шаблон:Div col end

References

Шаблон:Reflist

Шаблон:Cannabinoids Шаблон:Cannabinoidergics